Technology area: Biotechnology & Pharmaceuticals
33 pending office actions • 30 art units • 32 examiners • 0 of 33 (0%) have an AI response strategy ready • 22 patents granted in the last 365 days
Cambridge Enterprise Limited has 35 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 34 distinct examiners and 31 distinct art units, reflecting broad dispersion across both examiner assignments and technical examination groups. This profile favors centralized docket oversight supported by matter-level technical analysis.
MONTGOMERY, ANN Y is the busiest examiner, with 2 pending matters. The modest examiner concentration means that counsel should not rely on one examiner relationship, while the art-unit distribution can help organize recurring claim, prior-art, and amendment issues.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 7 (21%) |
| §103 only | 7 (21%) |
| §102 only | 1 (3%) |
| §112 only | 2 (6%) |
| Double-patenting + other | 1 (3%) |
| Multi-statute (no §101) | 14 (42%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTGOMERY, ANN Y | 2 | 69.1% | +27.6% |
| VAZQUEZ, ANA M | 1 | 80.0% | +17.7% |
| FLORA, NURUN N | 1 | 86.0% | +1.9% |
| WILLIAMS, KEITH RICHARD | 1 | 50.0% | +0.0% |
| STEPHENS, MATTHEW | 1 | 65.1% | +21.6% |
| WOOLWINE, SAMUEL C | 1 | 61.0% | +20.3% |
| MCGUIRK, JOHN SCHUYLER | 1 | 77.8% | +49.3% |
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| DAUNER, JOSEPH G | 1 | 57.0% | +35.3% |
| D'ANIELLO, NICHOLAS P | 1 | 68.3% | +41.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18993158 | 3D SCENE CAPTURE SYSTEM | FLORA, NURUN N | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17764145 | MULTIDIMENSIONAL MICROFLUIDIC PROTEIN CHARACTERISATION | VANNI, GEORGE STEVEN | 126d overdue |
| 18033225 | GHOST IMAGE FREE PROJECTION AT ARBITRARY DISTANCE | JORDAN, DANIEL JEFFERY | 11d overdue |
| 18485192 | METHODS AND DEVICES FOR GENERATING EMBRYOS IN VITRO FROM EMBRYONIC STEM CELLS | JACKSON III, WALTER | 4d overdue |
| 18460022 | METHODS AND COMPOSITIONS FOR GENERATING EMBRYOS IN VITRO FROM PLURIPOTENT STEM CELLS | VIJAYARAGHAVAN, JAGAMYA NMN | 12d |
| 18001655 | THERAPEUTIC TREATMENT USING PROTEIN KINASE C (PKC) INHIBITORS AND CYTOTOXIC AGENTS | BRANDSEN, BENJAMIN MICHAEL | 34d |
| 19115426 | Absorption Induced Caloric Effects and Uses Thereof | VAZQUEZ, ANA M | — |
| 18868448 | GLUCAN BINDING PROTEIN FOR IMPROVING NITROGEN FIXATION IN PLANTS | WILLIAMS, KEITH RICHARD | — |
| 18787165 | WORKING OF SHEET METAL | STEPHENS, MATTHEW | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19115426 | Absorption Induced Caloric Effects and Uses Thereof | VAZQUEZ, ANA M | — |
| 18787165 | WORKING OF SHEET METAL | STEPHENS, MATTHEW | — |
| 18714695 | ASSAY | WOOLWINE, SAMUEL C | — |
| 18706270 | METHOD OF DETECTING PROTEIN AGGREGATES | MCGUIRK, JOHN SCHUYLER | — |
| 18696136 | NUCLEIC ACID CHARACTERISATION | DAUNER, JOSEPH G | — |
| 18690688 | Lithium Sulfur Cell | D'ANIELLO, NICHOLAS P | — |
| 18277000 | IMPROVEMENTS IN OR RELATING TO A METHOD OF ANALYSING A COMPONENT IN A SAMPLE | MONTGOMERY, ANN Y | — |
| 17923594 | CARRIER SYSTEM AND METHOD | MONTGOMERY, ANN Y | — |
| Art Unit | Apps |
|---|---|
| 1798 | 2 |
| 1678 | 2 |
| 1693 | 2 |
| 3763 | 1 |
| 2619 | 1 |
| 1663 | 1 |
| 3725 | 1 |
| 1681 | 1 |
| 1672 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19115426 | Absorption Induced Caloric Effects and Uses Thereof | VAZQUEZ, ANA M | 3763 | §102§103§112 | Non-Final OA | — | Pending | Mar 26, 2025 |
| 18993158 | 3D SCENE CAPTURE SYSTEM | FLORA, NURUN N | 2619 | §102 | Non-Final OA | — | Pending | Jan 10, 2025 |
| 18868448 | GLUCAN BINDING PROTEIN FOR IMPROVING NITROGEN FIXATION IN PLANTS | WILLIAMS, KEITH RICHARD | 1663 | §101§112 | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18787165 | WORKING OF SHEET METAL | STEPHENS, MATTHEW | 3725 | §102§103§112Other | Final Rejection | — | Pending | Jul 29, 2024 |
| 18714695 | ASSAY | WOOLWINE, SAMUEL C | 1681 | §101§103§112 | Non-Final OA | — | Pending | May 30, 2024 |
| 18706270 | METHOD OF DETECTING PROTEIN AGGREGATES | MCGUIRK, JOHN SCHUYLER | 1798 | §101§103§112 | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18699032 | INFLUENZA VACCINES | CHESTNUT, BARRY A | 1672 | Other | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18696136 | NUCLEIC ACID CHARACTERISATION | DAUNER, JOSEPH G | 1682 | §102§103§112 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18690688 | Lithium Sulfur Cell | D'ANIELLO, NICHOLAS P | 1725 | §102§112 | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18685450 | TRANSMEMBRANE DEVICE | NGUYEN, HENRY H | 1758 | §102§103§112 | Non-Final OA | — | Pending | Feb 21, 2024 |
| 18568457 | METHODS OF EUKARYOTIC GENE EXPRESSION | KNIGHT, TERESA E | 1634 | §112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18568243 | Treatment or Prevention of Ischaemia Reperfusion Injury | NEAGU, IRINA | 1629 | §103DP | Final Rejection | — | Pending | Dec 07, 2023 |
| 18287686 | Method and System for Robot Navigation in Unknown Environments | LEVEL, BARBARA HENRY | 2875 | §101§112Other | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18485192 | METHODS AND DEVICES FOR GENERATING EMBRYOS IN VITRO FROM EMBRYONIC STEM CELLS | JACKSON III, WALTER | 1638 | §101§103 | Final Rejection | 4d overdue | Pending | Oct 11, 2023 |
| 18460022 | METHODS AND COMPOSITIONS FOR GENERATING EMBRYOS IN VITRO FROM PLURIPOTENT STEM CELLS | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §101§103§112Other | Non-Final OA | 12d | Pending | Sep 01, 2023 |
| 18546761 | Methods of Expanding Cholangiocytes | STAVROU, CONSTANTINA E | 1632 | §102§103 | Non-Final OA | — | Pending | Aug 16, 2023 |
| 18277000 | IMPROVEMENTS IN OR RELATING TO A METHOD OF ANALYSING A COMPONENT IN A SAMPLE | MONTGOMERY, ANN Y | 1678 | §103 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18276848 | RNA Trans-Splicing Molecule | TRAN, CHRISTINA L | 1637 | §103§112 | Non-Final OA | — | Pending | Aug 10, 2023 |
| 18320150 | PROTEINS FOR REGULATION OF SYMBIOTIC NODULE ORGAN IDENTITY | DELEO, VICTORIA LYNN | 1662 | §102§103§112 | Non-Final OA | — | Pending | May 18, 2023 |
| 18033225 | GHOST IMAGE FREE PROJECTION AT ARBITRARY DISTANCE | JORDAN, DANIEL JEFFERY | 2872 | §102§103 | Final Rejection | 11d overdue | Pending | Apr 21, 2023 |
| 18014701 | INTERFEROMETRIC SCATTERING CORRELATION (ISCORR) MICROSCOPY | AMARA, MOHAMED K | 2877 | §103 | Non-Final OA | 71d overdue | Pending | Jan 05, 2023 |
| 18001655 | THERAPEUTIC TREATMENT USING PROTEIN KINASE C (PKC) INHIBITORS AND CYTOTOXIC AGENTS | BRANDSEN, BENJAMIN MICHAEL | 1693 | §102§103 | Non-Final OA | 34d | Pending | Dec 13, 2022 |
| 17999478 | METHOD AND APPARATUS FOR MEASURING PHASE TRANSITION CHARACTERISTICS OF MACROMOLECULES | GZYBOWSKI, MICHAEL STANLEY | 1798 | §103 | Non-Final OA | 7d | Pending | Nov 21, 2022 |
| 17926915 | MODE LOCALISED ACCELEROMETER | PARCO JR, RUBEN C | 2853 | §103 | Final Rejection | 65d | Pending | Nov 21, 2022 |
| 17923594 | CARRIER SYSTEM AND METHOD | MONTGOMERY, ANN Y | 1678 | §112 | Non-Final OA | — | Pending | Nov 06, 2022 |
| 17917165 | METHOD OF ADDITIVE LAYER MANUFACTURING | SPENCER, MAXIMILIAN TOBIAS | 3774 | §102§103§112 | Final Rejection | — | Pending | Oct 05, 2022 |
| 17916323 | INFLUENZA VACCINES | BLUMEL, BENJAMIN P | 1671 | §103§112 | Final Rejection | — | Pending | Sep 30, 2022 |
| 17799320 | USE OF COMPOUNDS THAT ARE ABLE TO CROSS-LINK THE EXTRACELLULAR MATRIX FOR PREVENTING OR INHIBITING THE MIGRATION OF CANCER CELLS | CHO, DAVID H | 1693 | §103Other | Final Rejection | — | Pending | Aug 12, 2022 |
| 17772526 | AN EXTRACELLULAR VESICLE | D' AMBROSIO, THEA | 1654 | §102§103§112 | Final Rejection | — | Pending | Apr 28, 2022 |
| 17764145 | MULTIDIMENSIONAL MICROFLUIDIC PROTEIN CHARACTERISATION | VANNI, GEORGE STEVEN | 1686 | §101§102§103§112 | Non-Final OA | 126d overdue | Pending | Mar 25, 2022 |
| 17633889 | LIQUID DRESSING COMPOSITIONS AND THEIR USES | COHEN, MICHAEL P | 1612 | §103 | Non-Final OA | 100d overdue | Pending | Feb 08, 2022 |
| 17626058 | MEDICAL DEVICE | LEE, DAVINA EN-YIN | 3794 | §103§112 | Final Rejection | — | Pending | Jan 10, 2022 |
| 17398221 | INTEGRATED CLOSED-LOOP MEDICATION DELIVERY WITH ERROR MODEL AND SAFETY CHECK | VU, QUYNH-NHU HOANG | 3783 | §103 | Final Rejection | — | Pending | Aug 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCambridge Enterprise Limited has 33 pending office actions as of October 2026, spread across 30 art units and 32 examiners.
Ann Y Montgomery has the most, with 2 of Cambridge Enterprise Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
